Q1/11 Results, Aastrom Biosciences (ASTM)
There were no revenues in Q1/11 while R&D costs were $4.17M with SG&A clocking in at $1.7M. Total operating expenses were $5.85M. The net loss was based on a basic and diluted count of 28.25M shares. R&D expenses for Q1/10 were $2.9M with SG&A costs of $0.9M in Q1/10. This increase was associated with preparations for the Phase 3 CLI development program. This change is due to a $0.4M increase in non-cash stock-based compensation expense with the remainder primarily due to higher employee expenses and general consulting. (ASTM has a June calendar year)
- As of 9/30/10, ASTM had a total of approximately $14.5M in cash and cash equivalents; compared to $19.1M in cash, cash equivalents and short-term investments at 6/30/10.
Net loss for Q1/10 was $3.8M or ($0.18) per share for comparison purposes. Loss per share comparisons were impacted by the issuance of 6.5M shares of common stock on 1/21/10.
- ASTM closed at $2.83 on 11/5/10, up $0.29 or 11.42%.